BMJ Open (Jul 2021)

Using a pragmatically adapted, low-cost contingency management intervention to promote heroin abstinence in individuals undergoing treatment for heroin use disorder in UK drug services (PRAISE): a cluster randomised trial

  • Julian Mutz,
  • Andrew Pickles,
  • Sarah Byford,
  • John Dunn,
  • Kimberley Goldsmith,
  • Franziska Mosler,
  • Tim Weaver,
  • James Shearer,
  • Emily Finch,
  • John Strang,
  • Clare Davey,
  • Stephen Pilling,
  • Anthony Glasper,
  • Nicola Metrebian,
  • Jennifer Hellier,
  • Luke Mitcheson,
  • Prun Bijral,
  • Nadine Bogdan,
  • Owen Bowden-Jones,
  • Edward Day,
  • Sam Forshall,
  • Shabana Akhtar,
  • Jalpa Bajaria,
  • Carmel Bennett,
  • Elizabeth Bishop,
  • Vikki Charles,
  • Roopal Desai,
  • Claire Goodfellow,
  • Farjana Haque,
  • Nicholas Little,
  • Hortencia McKechnie,
  • Jo Morris,
  • Ruth Pauli,
  • Dilkushi Poovendran,
  • Elizabeth Phillips

DOI
https://doi.org/10.1136/bmjopen-2020-046371
Journal volume & issue
Vol. 11, no. 7

Abstract

Read online

Introduction Most individuals treated for heroin use disorder receive opioid agonist treatment (OAT)(methadone or buprenorphine). However, OAT is associated with high attrition and persistent, occasional heroin use. There is some evidence for the effectiveness of contingency management (CM), a behavioural intervention involving modest financial incentives, in encouraging drug abstinence when applied adjunctively with OAT. UK drug services have a minimal track record of applying CM and limited resources to implement it. We assessed a CM intervention pragmatically adapted for ease of implementation in UK drug services to promote heroin abstinence among individuals receiving OAT.Design Cluster randomised controlled trial.Setting and participants 552 adults with heroin use disorder (target 660) enrolled from 34 clusters (drug treatment clinics) in England between November 2012 and October 2015.Interventions Clusters were randomly allocated 1:1:1 to OAT plus 12× weekly appointments with: (1) CM targeted at opiate abstinence at appointments (CM Abstinence); (2) CM targeted at on-time attendance at appointments (CM Attendance); or (3) no CM (treatment as usual; TAU). Modifications included monitoring behaviour weekly and fixed incentives schedule.Measurements Primary outcome: heroin abstinence measured by heroin-free urines (weeks 9–12). Secondary outcomes: heroin abstinence 12 weeks after discontinuation of CM (weeks 21–24); attendance; self-reported drug use, physical and mental health.Results CM Attendance was superior to TAU in encouraging heroin abstinence. Odds of a heroin-negative urine in weeks 9–12 was statistically significantly greater in CM Attendance compared with TAU (OR=2.1; 95% CI 1.1 to 3.9; p=0.030). CM Abstinence was not superior to TAU (OR=1.6; 95% CI 0.9 to 3.0; p=0.146) or CM Attendance (OR=1.3; 95% CI 0.7 to 2.4; p=0.438) (not statistically significant differences). Reductions in heroin use were not sustained at 21–24 weeks. No differences between groups in self-reported heroin use.Conclusions A pragmatically adapted CM intervention for routine use in UK drug services was moderately effective in encouraging heroin abstinence compared with no CM only when targeted at attendance. CM targeted at abstinence was not effective.Trial registration number ISRCTN 01591254.